

COMPANY OVERVIEW

Avalo Therapeutics, Inc. (AVTX) is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in the areas of Immunology, Immuno-oncology, and Rare Genetic Diseases.

RECENT NEWS

Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit

Oct 13 2021, 7:00 AM EDT

Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference

Sep 20 2021, 7:00 AM EDT

STOCK OVERVIEW

Symbol	AVTX
Exchange	Nasdaq
Market Cap	251.59m
Last Price	\$2.24
52-Week Range	\$1.98 - \$4.50

10/19/2021 04:00 PM EDT

INVESTOR RELATIONS

ir@avalotx.com

AVALO THERAPEUTICS, INC.

1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.